Parody in Pale Fire

作为二十世纪最出色的作家、文体家和文学评论家之一，弗拉基米尔•纳博科夫一生中创作了大量的文学作品。其中包括长篇小说、诗歌、戏剧、短片小说、翻译、散文和文学评论。但纳博科夫主要还是以长篇小说闻名于世，如《洛丽塔》、《普宁》、《微暗的火》等都无疑已成为文学史上的经典佳作。总体来讲，大部分纳博科夫的小说都着重于探讨一个共同主题，即现实的虚构本质以及作家向读者揭示这一本质的艺术方法。在这些经典小说中，《微暗的火》是设计布局最为精巧、结构最为奇特的一部。自1962年面世以来，关于这部小说的热烈探讨和各方评论就从未停息过。因此，本文以纳博科夫在《微暗的火》中对戏仿的运用为突破口，分析了其文学创...Regarded as one of the world’s most distinctive writers, stylists and critics of the 20th century, Vladimir Nabokov has written a large number of works during his life-long literary career. His works include novels, poems, plays, short stories, translations, essays and literary reviews, among which the English novels, such as Lolita, Pnin and Pale Fire, have established a world-wide reputation for...学位：文学硕士院系专业：外文学院_外国语言学及应用语言学学号：1232010115257

A Silver Nanoparticle-Enhanced Fluorimetry for Determination of Trace Enrofloxacin in Water

在实验条件下建立了水溶液中痕量恩诺沙星的荧光分析方法;在课题组已有工作的基础上,采用“绿色“化学方法合成了银纳米粒子;研究了所制得的银纳米粒子对水溶液中恩诺沙星荧光行为的影响,并最终建立了水溶液中痕量恩诺沙星的银纳米粒子增强荧光分析方法。Firstly, a fluorimetry for determination of trace enrofloxacin in water was established in laboratory conditions.Secondly, the silver nanoparticle was synthesized based on our previous studies.In addition, effect of silver nanoparticle on the fluorescence behavior of enrofloxacin in water was investigated.Finally, a silver nanoparticle-enhanced fluorimetry for determination of trace enrofloxacin in water was also established.国家自然科学基金项目;项目号:21207103; 浙江省大学生科技创新活动计划暨新苗人才计划;项目号:2013R413010; 浙江省公益项目;项目号:2012C31025

中国科学院心理研究所会议论文集

大量研究发现注意偏向矫正(attention bias modification,ABM)训练对社交焦虑障碍的个体有很好的治疗效果,训练能够改变负性注意偏向,减轻焦虑症状。但ABM训练改善焦虑症状的内在机制仍不清楚,有研究表明注意控制功能和情绪效价加工是两个可能的ABM训练的介导机制。本研究以社交焦虑障碍个体为研究对象,将其随机分为训练组(ABM训练)和控制组(注意偏向保持训练),在训练的前后测中&nbsp;</p

中国心理学会会议论文集

大量研究发现注意偏向矫正(attention bias modification,ABM)训练对社交焦虑障碍的个体有很好的治疗效果,训练能够改变负性注意偏向,减轻焦虑症状。但ABM训练改善焦虑症状的内在机制仍不清楚,有研究表明注意控制功能和情绪效价加工是两个可能的ABM训练的介导机制。本研究以社交焦虑障碍个体为研究对象,将其随机分为训练组(ABM训练)和控制组(注意偏向保持训练),在训练的前后测中&nbsp;</p

中国科学院心理研究所会议论文集

大量研究发现注意偏向矫正(attention bias modification,ABM)训练改善社交焦虑障碍的个体的焦虑症状和负性的注意偏向,是以影响注意控制能力为介导机制的。但以往的研究大多忽略了情绪加工与注意控制加工之间的交互作用,ABM训练对情绪参与的注意控制能力产生了怎样的影响,我们仍不清楚。本研究以社交焦虑障碍的临床病人为研究对象,将其随机分为训练组(ABM训练)和控制组(注意偏向保持&nbsp;</p

SOA全光波长转换技术研究及其发展

全光波长转换技术在波分复用网络中有着非常重要的作用,尤其是基于SOA（半导体光放大器）的全光波长转换技术,已有较为成熟的理论研究,但其性能上仍存在很多不足。文章对基于SOA的全光波长转换技术的原理和性能特点进行了分析和比较。由最基础的不同类型的基于SOA的全光波长转换技术扩展到改进的技术方案,对不同结构和类型的全光波长转换技术进行了特性分析和比较,并对它们的应用前景和发展方向进行了展望。结果表明,通过改变SOA的增益特性或者改变系统结构,均能在不同方面改善全光波长转换技术的性能参数

草炭绿化荒漠

1993-1996年与日本草炭研究会开始“草炭绿化荒漠”的研究工作,1997-2000年开始执行中日政府间JICA合作研究,1998年9月-2001年9月开始中国科学院重大国际合作特别支持项目。该项目以中国科学院阜康荒漠生态试验站为基地,利用草炭改良荒漠,寻求绿化荒漠的新方法、新技术,改善干旱区环境为目的。研究包括草炭的基本性质、土壤-植物系统与水份关系、草炭改土效果、草炭制剂的研究制、草炭利用新技术、草炭的土壤中分解速率和利用年限、草炭绿化荒漠机理等。研制的“草炭土壤调理剂”获发明专利,该制剂可为作物提供全方位的水份和养份供应,为有机肥工业化提供了良好前景;研究方法上采用了盆栽、小区和同位素..

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials